Loading…
BridgeBio Pharma, Inc. is projected to rise to $110.01 by 2027, a +34% move from its current price of $82.14. BBIO is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $80.51 | $82.17 | $83.86 | +0.04% |
| Aug 2 | $79.87 | $82.20 | $84.60 | +0.07% |
| Aug 3 | $79.38 | $82.23 | $85.19 | +0.11% |
| Aug 4 | $78.98 | $82.26 | $85.68 | +0.15% |
| Aug 5 | $78.63 | $82.29 | $86.13 | +0.19% |
| Aug 6 | $78.31 | $82.32 | $86.54 | +0.22% |
| Aug 7 | $78.03 | $82.35 | $86.91 | +0.26% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $78.03 | $82.35 | $86.91 | +0.26% |
| Week 2 | $76.50 | $82.57 | $89.11 | +0.52% |
| Week 3 | $75.40 | $82.78 | $90.88 | +0.78% |
| Week 4 | $74.51 | $82.99 | $92.44 | +1.04% |
| Week 5 | $73.76 | $83.21 | $93.87 | +1.30% |
| Week 6 | $73.10 | $83.43 | $95.20 | +1.56% |
| Week 7 | $72.52 | $83.64 | $96.47 | +1.83% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BridgeBio Pharma, Inc. is a biopharmaceutical company that discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage for the treatment of children with achondroplasia and hypochondroplasia.
It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd.
BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
BridgeBio Pharma, Inc. trades at $82.66 and has a market capitalization of $16.19B, ranking 682. The stock faces a bullish long-term forecast, with the average price rising across multiple years and substantial upside potential.
The 2026 forecast shows an average price of $82.66, with the 2027-2050 path delivering higher averages and strong ROI, including 2030 average of $195.72 and 2050 average of $1,427.31. The projected ranges across the years indicate meaningful volatility and upside, with 2026 min and max of $63.73 and $113.65, respectively, and 2050 max of $2,574.25.
A major floor 32.3% below — a decisive break under it would weaken the trend.
The nearest floor, 19.3% below — buyers have tended to step in here.
The nearest ceiling, 9.8% above — a clean break opens room to run.
A major ceiling 25.9% above — clearing it would confirm fresh momentum.
Key BBIO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BBIO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $83.87 | Sell | $83.31 | Sell |
| MA 10 | $82.96 | Sell | $82.96 | Sell |
| MA 20 | $82.35 | Sell | $81.09 | Buy |
| MA 50 | $73.84 | Buy | $76.62 | Buy |
| MA 100 | $72.59 | Buy | $73.62 | Buy |
| MA 200 | $71.26 | Buy | $68.57 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 56.31 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -5.97 | Neutral |
| Williams %R (14) | -64.95 | Info |
| MACD (12,26,9) | -0.39 | Sell |
| ROC (12) | -2.32 | Sell |
| Bollinger %B (20,2) | 0.48 | Neutral |
| Stochastic %K (14) | 35.05 | Neutral |
| TRIX (15) | 0.64 | Buy |
| Awesome (5,34) | 6.89 | Buy |
| Ultimate (7,14,28) | 48.03 | Neutral |
| Momentum (10) | 1.84 | Buy |
| Aroon Osc (25) | 40.00 | Buy |
| Hull MA (9) | 84.29 | Sell |
| ADX (14) | 25.49 | Buy |
| ATR (14) | 1.48 | Info |
The sentiment is bullish, with RSI(14) at 60 and the stock trading above near-term moving averages. The SMA50 is $70.46 and the SMA200 is $69.65, suggesting a constructive trend. Immediate support sits at $63.88, while resistance is at $90.17.
The last 30 days have seen a range from $69.86 to $97.81, highlighting near-term upside potential but with some volatility.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $63.73 | $82.14 | $110.98 | 0% | Neutral | |
| $89.75 | $110.01 | $141.23 | +34% | Bullish | |
| $120.05 | $150.19 | $198.50 | +83% | Bullish | |
| $135.86 | $172.86 | $233.73 | +110% | Bullish | |
| $145.44 | $187.80 | $258.86 | +129% | Bullish | |
| $168.31 | $220.24 | $308.73 | +168% | Bullish | |
| $179.91 | $238.33 | $339.20 | +190% | Bullish | |
| $199.55 | $267.41 | $385.86 | +226% | Bullish | |
| $237.53 | $321.80 | $470.27 | +292% | Bullish | |
| $272.12 | $372.49 | $550.83 | +353% | Bullish | |
| $390.08 | $559.29 | $869.38 | +581% | Bullish | |
| $864.39 | $1,339.18 | $2,240.78 | +15.3x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $63.73 | $82.14 | $95.78 | +0.00% |
| August 2026 | $72.86 | $85.06 | $101.27 | +3.55% |
| September 2026 | $72.33 | $84.96 | $102.18 | -0.12% |
| October 2026 | $73.08 | $86.27 | $104.59 | +1.55% |
| November 2026 | $75.49 | $89.48 | $109.19 | +3.72% |
| December 2026 | $76.00 | $90.42 | $110.98 | +1.05% |
Click any year to see its month-by-month BBIO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect BBIO to range from $63.73 to $110.98 through 2026. The $82.14 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The BBIO price prediction for 2027 points to an average of $110.01 (low $89.75, high $141.23) — a potential gain of +34% on today's $82.14. Momentum favours further upside here.
In 2028, BBIO is projected to trade between $120.05 and $198.50, averaging $150.19 — a potential gain of +83% from today's $82.14. That is up +37% on the projected 2027 average. Buyers look set to stay in control over this stretch.
BridgeBio Pharma, Inc.'s 2029 outlook centres on $172.86, within a $135.86 to $233.73 range. That is up +15% on the projected 2028 average. That marks a +110% change versus current levels. Momentum favours further upside here.
By 2030, BBIO could reach as high as $258.86, with a base case around $187.80 and support toward $145.44 — roughly +129% from $82.14. Buyers look set to stay in control over this stretch.
Expect BBIO to range from $168.31 to $308.73 through 2031. The $220.24 average target implies a +168% move from current prices. That is up +17% on the projected 2030 average. Momentum favours further upside here.
The BBIO price prediction for 2032 points to an average of $238.33 (low $179.91, high $339.20) — a potential gain of +190% on today's $82.14. Buyers look set to stay in control over this stretch.
In 2033, BBIO is projected to trade between $199.55 and $385.86, averaging $267.41 — a potential gain of +226% from today's $82.14. That is up +12% on the projected 2032 average. Momentum favours further upside here.
BridgeBio Pharma, Inc.'s 2034 outlook centres on $321.80, within a $237.53 to $470.27 range. That is up +20% on the projected 2033 average. That marks a +292% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, BBIO could reach as high as $550.83, with a base case around $372.49 and support toward $272.12 — roughly +353% from $82.14. Momentum favours further upside here.
Expect BBIO to range from $390.08 to $869.38 through 2040. The $559.29 average target implies a +581% move from current prices. That is up +50% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The BBIO price prediction for 2050 points to an average of $1,339.18 (low $864.39, high $2,240.78) — a potential gain of +15.3x on today's $82.14. Momentum favours further upside here.
Investing $1,000 in BBIO today (≈ 12.174336 BBIO) could be worth
$16,303.68
+$15,303.68 (+1530%) by 2050 · US Dollar
Based on the average projected BBIO price of $1,339.18 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BBIOwould be worth at today's price.
$1,000 invested in BBIO on Jul 30, 2025 (≈ 21.920211 BBIO) would be worth
$1,800.53
+$800.53 (+80.1%) today · 1.80× · US Dollar
Based on a BBIO entry price of $45.62 vs. today's $82.14.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $82.93 | $990.47 | -1.0% |
| 1 month ago | $74.48 | $1,102.85 | +10.3% |
| 3 months ago | $68.56 | $1,198.07 | +19.8% |
| 6 months ago | $77.27 | $1,063.03 | +6.3% |
| 1 year ago | $45.62 | $1,800.53 | +80.1% |
| All time (5.0y) ago | $52.33 | $1,569.65 | +57.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BBIO forecast.
Our base-case forecast reaches $160.00 around 2029.
Implied market cap at $160.00: $31.34B
The multi-year forecast shows a bullish trajectory with rising averages and sizable upside. The 2026 average is $82.66, followed by 2027 at $114.60, 2028 at $158.84, 2029 at $178.97, and 2030 at $195.72. By 2040 the average is projected at $594.29, and by 2050 it could reach $1,427.31.
Corresponding ROI figures rise from 0% in 2026 to 136.8% in 2030, 619% in 2040, and 1626.7% in 2050, reflecting a strong long-term upside. These figures are forecasts and not guarantees; actual results will vary with market conditions and company developments.
Tap a question to reveal the answer.
Avg $195.72, min $146.74, max $280.84, ROI 136.8%.
The forecast shows a bullish path with rising averages and high potential ROI (e.g., 2027 avg $114.60; 2030 avg $195.72; 2040 avg $594.29; 2050 avg $1,427.31; ROI up to 1626.7%). These are not guarantees.
Yes. The forecast shows 2027 max $150.96 and 2028 avg $158.84, indicating potential to surpass $150 under the projected path.
30-day range low $69.86, high $97.81.
2040 avg $594.29; ROI 619%. 2050 avg $1,427.31; ROI 1626.7%.
BridgeBio Pharma, Inc. Community Discussion
0Share your BridgeBio Pharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.